Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL8153725 | 0.94 | OPRM1 (0.41) | OPRM1HTR2AGRIN1GRIN2AGRIN2B | |
| SCHEMBL27306600 | 0.93 | OPRM1 (0.43) | OPRM1HTR2AGRIN1GRIN2AGRIN2B | |
| SCHEMBL4780555 | 0.88 | OPRM1 (0.50) | OPRM1HTR2ADPP4AKR1C1NPY5R | |
| SCHEMBL1670566 | 0.86 | OPRM1 (0.35) | OPRM1HTR2AGRIN1GRIN2AGRIN2B | |
| Methyl Alcohol SCHEMBL8520431 | 0.82 | OPRM1 (0.45) | OPRM1HTR2AAKR1C1NPY5ROPRK1 | |
| SCHEMBL1958095 | 0.78 | OPRM1 (0.57) | OPRM1HTR2ANPY5R | |
| SCHEMBL1959361 | 0.77 | HTR2A (0.47) | OPRM1HTR2ANPY5R | |
| SCHEMBL28175729 | 0.76 | OPRM1 (0.43) | OPRM1HTR2AGRIN1GRIN2AGRIN2B | |
| SCHEMBL9198597 | 0.75 | AKR1B1 (0.50) | HTR2A | |
| SCHEMBL15995119 | 0.74 | OPRM1 (0.42) | OPRM1HTR2AGRIN1GRIN2AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| US-5714500-A | 2-phenyl- and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties | ASTRA AB (SE) | 1998-02-03 | — | — | US | disclosed |
| EP-0553278-B1 | 2-PHENYL-AND 2-THIENYL-(2)-PIPERIDINE DERIVATIVES HAVING NEUROPROTECTIVE PROPERTIES | ASTRA AB (SE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0588850-A1 | N-HYDROXYUREA DERIVATIVES WHICH INHIBIT LIPOXYGENASE. | PFIZER (US) | 1994-03-30 | — | — | EP | disclosed |
| EP-0553278-A1 | 2-PHENYL-AND 2-THIENYL-(2)-PIPERIDINE DERIVATIVES HAVING NEUROPROTECTIVE PROPERTIES. | FISONS CORP (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992022543-A1 | N-HYDROXYUREA DERIVATIVES WHICH INHIBIT LIPOXYGENASE | PFIZER INC. (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992006957-A1 | 2-PHENYL-AND 2-THIENYL-(2)-PIPERIDINE DERIVATIVES HAVING NEUROPROTECTIVE PROPERTIES | FISONS CORPORATION (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | OPRM1 389/4885HTR2A 719/4885GRIN1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.